Heather Landi

5 hours ago | fiercehealthcare.com | Heather Landi

The team at Omada Health took a victory lap Friday after the company's successful Nasdaq debut, according to company president Wei-Li Shao. But the work doesn't stop as the digital health company focuses on expanding its virtual chronic condition services to more patients. The company closed its first day of trading at $23 per share, a 21% jump from the IPO price of $19 per share, securing a valuation just over $1 billion. Reuters reported Omada Health's valuation hit $1.28 billion.

1 day ago | fiercehealthcare.com | Heather Landi

Neuroscience technology company Brooklyn Health is using artificial intelligence to target a fundamental problem in neurology and psychiatry: the flawed approach to mental health outcomes measurement. The startup aims to modernize mental health measurement and scoring in central nervous system (CNS) drug development, an area of CNS research that faces limitations in objectivity and standardization.

2 days ago | fiercehealthcare.com | Heather Landi

Artificial intelligence startup OpenEvidence inked a multi-year content agreement with the JAMA Network to use content from 13 medical journals to inform answers on its platform. OpenEvidence developed an AI-powered medical search engine and generative AI chatbot exclusively for doctors that summarizes and simplifies evidence-based medical information.

2 days ago | fiercebiotech.com | Heather Landi

Startup Clairity scored a greenlight from the FDA for the agency's first artificial intelligence tool designed to predict five-year breast cancer risk from a routine screening mammogram. According to the company, the FDA’s de novo clearance paves the way for Clairity to launch the risk prediction platform with leading health systems through 2025.

2 days ago | fiercebiotech.com | Heather Landi

Smiths Medical has recalled ambulatory infusion pumps to provide updated use instructions to providers after identifying issues with potential false alarms as well as two other problems that could pose safety risks. The Food and Drug Administration classified each of them as Class I recalls, its most serious type. Smiths Medical has not reported any serious injuries or deaths related to these issues, but the FDA determined there is a risk of harm. The devices are staying on the market.